Monday, June 29, 2009

Oral PARP Inhibitor Shows Anti-Tumor Results

In an early, Phase 1 trial at Royal Marsden Hospital in London and Netherlands Cancer Institute, an oral PARP inhibitor drug (part of a new generation of anti-cancer drugs being developed) showed anti-tumor activity against BRCA1 and BRCA2 related breast, prostate and ovarian cancers. It also showed acceptable side effects and low toxicity.

Read the article in NEJM - its a freebie! Link

No comments:

Post a Comment